Attenuating The Post-Operative Insulin Resistance And Promoting Protein Anabolism

Insulin Resistance Clinical Trial

Official title: Attenuating The Post-Operative Insulin Resistance And Promoting Protein Anabolism In Patients Undergoing Major Lung or Abdominal Surgery

Status Terminated

Clinical Trial Summary

Major surgery results in a stress- induced catabolic response, marked by post-operative insulin resistance, hyperglycemia and loss of body protein, which is associated with increased morbidity, mortality and adverse outcomes. There has been a great deal of research on different approaches to optimize post-operative insulin sensitivity including hormonal and nutritional interventions, minimally invasive surgical techniques and epidural anesthesia. However, the correlation between insulin resistance and body protein loss is not well understood. Metformin is the most widely used insulin sensitizing and blood glucose-lowering drug in treatment of type 2 diabetic patients. This study will: 1) estimate the correlation between insulin resistance and body protein loss in pre-diabetic lung/colorectal resection patients; 2) investigate whether the post-operative metabolic state can be improved by the pre-operative administration of metformin; and assess the impact of metformin on surgical complications and hospital length of stay. The results of this study will provide insight into the relationship between insulin resistance and post-operative adverse events and potentially suggest a novel approach to improve outcomes using Metformin, a drug already in wide clinical use.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Glucose Intolerance
• Insulin Resistance
• Major Lung or Abdominal Surgery
• Pre-Diabetes
• Prediabetic State

• NCT number: NCT02393573
• Study type: Interventional
• Source: McGill University Health Center
• Status: Terminated
• Phase: N/A
• Start date: November 2015
• Completion date: March 2018